Aktienanalyse zu Novo Nordisk A/S (NVO)NVONovo Nordisk A/S

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Novo Nordisk is currently a hold. The stock is trading at $38.64, which is below the analyst price target of $40 from Morgan Stanley, indicating limited upside. Additionally, the forward P/E ratio is 11.83, suggesting it may be undervalued, but the company faces significant competition from Eli Lilly, which could impact future growth.

1 analysts cover NVO: 0 rate it Buy, 1 Hold and 0 Sell. The average price target is 54.67.